Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

Compare

0.2091

-0.0081 (-3.73%)

At close: Feb 12, 2026, 4:00 PM EST

0.2197

+0.0106 (5.07%)

After-hours: Feb 12, 2026, 7:27 PM EST

Virax Biolabs Group Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	0	0.01	0.16	0.01	-	0.12
Revenue Growth (YoY)	-96.48%	-95.95%	1727.11%	-	-	23.97%
Cost of Revenue	0.05	0.06	0.11	0.01	-	0.13
Gross Profit	-0.05	-0.05	0.05	-0	-	-0.01
Selling, General & Admin	3.39	4.33	4.59	3.55	1.3	0.51
Research & Development	2.43	1.78	1.56	2.18	0.43	0.12
Operating Expenses	5.82	6.11	6.16	5.73	1.73	0.64
Operating Income	-5.87	-6.16	-6.11	-5.73	-1.73	-0.64
Interest Expense	-0.06	-0.06	-0.03	-0.02	-0.02	-0.03
Other Non Operating Income (Expenses)	0.01	0.02	-0.02	-0	-0	0
EBT Excluding Unusual Items	-5.93	-6.2	-6.15	-5.75	-1.75	-0.67
Asset Writedown	-	-	-0.39	-	-	-
Legal Settlements	-	-	-0.21	-	-	-
Other Unusual Items	-	-	0.01	0.29	-	-
Pretax Income	-5.93	-6.2	-6.74	-5.46	-1.75	-0.67
Income Tax Expense	-0.27	-0.14	-	-	-	-
Earnings From Continuing Operations	-5.65	-6.07	-6.74	-5.46	-1.75	-0.67
Minority Interest in Earnings	0.01	0.01	0.01	0	0.04	0.02
Net Income	-5.64	-6.06	-6.73	-5.46	-1.71	-0.65
Net Income to Common	-5.64	-6.06	-6.73	-5.46	-1.71	-0.65
Shares Outstanding (Basic)	5	4	2	1	1	0
Shares Outstanding (Diluted)	5	4	2	1	1	0
Shares Change (YoY)	70.75%	85.92%	88.75%	11.15%	297.67%	130.43%
EPS (Basic)	-1.24	-1.62	-3.36	-5.13	-1.79	-2.71
EPS (Diluted)	-1.24	-1.62	-3.36	-5.13	-1.79	-2.71
Free Cash Flow	-5.9	-5.17	-7.2	-4.18	-0.81	-0.59
Free Cash Flow Per Share	-1.29	-1.39	-3.59	-3.93	-0.85	-2.45
Gross Margin	-	-	32.34%	-15.94%	-	-7.62%
Operating Margin	-196566.68%	-97344.76%	-3903.69%	-66963.68%	-	-520.54%
Profit Margin	-189001.71%	-95739.17%	-4304.81%	-63748.32%	-	-525.75%
Free Cash Flow Margin	-197677.16%	-81621.64%	-4602.71%	-48823.35%	-	-476.65%
EBITDA	-5.56	-5.91	-6.05	-	-	-
D&A For EBITDA	0.31	0.26	0.05	-	-	-
EBIT	-5.87	-6.16	-6.11	-5.73	-1.73	-0.64
Revenue as Reported	-	-	-	-	-	0.12

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q